OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Jin Zhang M.D., Ph.D is editor at The Pharmaceutical Consultant.
Both foreign and domestic pharmas are in a race to bring PD-1/PD-L1 inhibitors into China, writes Jin Zhang.
Jin Zhang provides an overview of China's major bispecific antibody developers.
In the face of booming antibody market, China has jumped into the antibody-drug conjugate space. Jin Zhang reports.
Tyrosine-kinase inhibitors (TKIs) are gradually becoming the most popular option for lung cancer treatment in China. Jin Zhang reports.